Literature DB >> 23696036

Multi-country rapid adverse drug event assessment: the Asian Pharmacoepidemiology Network (AsPEN) antipsychotic and acute hyperglycaemia study.

Nicole Pratt1, Morten Andersen, Ulf Bergman, Nam-Kyong Choi, Tobias Gerhard, Cecilia Huang, Michio Kimura, Tomomi Kimura, Kiyoshi Kubota, Edward Chia-Cheng Lai, Nobuhiro Ooba, Urban Osby, Byung-Joo Park, Tsugumichi Sato, Ju-Young Shin, Anders Sundström, Yea-Huei Kao Yang, Elizabeth E Roughead.   

Abstract

PURPOSE: To undertake a multi-country study to investigate the risk of acute hyperglycaemia with antipsychotic use.
METHODS: Using a distributed network model with a common minimal data set, we performed a prescription sequence symmetry analysis (PSSA) to investigate the risk of acute hyperglycaemia associated with antipsychotic initiation. Incident insulin prescriptions were used as a proxy indicator of acute hyperglycaemia. Participating countries and population datasets included Australia (300,000 persons), Japan I (300,000 persons), Japan II (200,000 persons), Korea (53 million persons) Taiwan (1 million persons), Sweden (9 million persons), USA-Public (87 million persons) and USA-Private (47 million persons).
RESULTS: Olanzapine showed a trend towards increased risk in most databases, with a significant association observed in the USA-Public database (Adjusted sequence ratio (ASR) = 1.14; 95% Confidence Interval (CI) 1.10-1.17) and Sweden (ASR = 1.53; 95% CI 1.13-2.06). Null or negative associations were observed for haloperidol, quetiapine and risperidone.
CONCLUSION: Acute hyperglycaemia appears to be associated with olanzapine use, however, this effect was only observed in two large databases. Despite different patterns of utilization of both antipsychotics and insulin, PSSA analysis results for individual antipsychotic medicines were qualitatively similar across most countries. PSSA, used in conjunction with existing methods, may provide a simple and timely method further supporting multi-national drug safety monitoring.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Asian Pharmacoepidemiology Network (AsPEN); antipsychotics; distributed network model; hyperglycaemial; multi-national collaboration; pharmacoepidemiology; prescription sequence symmetry analysis

Mesh:

Substances:

Year:  2013        PMID: 23696036     DOI: 10.1002/pds.3440

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  22 in total

1.  Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database.

Authors:  Izyan A Wahab; Nicole L Pratt; Lisa Kalisch Ellett; Elizabeth E Roughead
Journal:  Drug Saf       Date:  2016-04       Impact factor: 5.606

2.  Transparent Reporting on Research Using Unstructured Electronic Health Record Data to Generate 'Real World' Evidence of Comparative Effectiveness and Safety.

Authors:  Shirley V Wang; Olga V Patterson; Joshua J Gagne; Jeffrey S Brown; Robert Ball; Pall Jonsson; Adam Wright; Li Zhou; Wim Goettsch; Andrew Bate
Journal:  Drug Saf       Date:  2019-11       Impact factor: 5.606

Review 3.  Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies.

Authors:  Edward Chia-Cheng Lai; Nicole Pratt; Cheng-Yang Hsieh; Swu-Jane Lin; Anton Pottegård; Elizabeth E Roughead; Yea-Huei Kao Yang; Jesper Hallas
Journal:  Eur J Epidemiol       Date:  2017-07-11       Impact factor: 8.082

4.  An Automated System Combining Safety Signal Detection and Prioritization from Healthcare Databases: A Pilot Study.

Authors:  Mickael Arnaud; Bernard Bégaud; Frantz Thiessard; Quentin Jarrion; Julien Bezin; Antoine Pariente; Francesco Salvo
Journal:  Drug Saf       Date:  2018-04       Impact factor: 5.606

5.  From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources.

Authors:  Gianluca Trifirò; Janet Sultana; Andrew Bate
Journal:  Drug Saf       Date:  2018-02       Impact factor: 5.606

6.  The Medicines Intelligence Centre of Research Excellence: Co-creating real-world evidence to support the evidentiary needs of Australian medicines regulators and payers.

Authors:  Nicole Pratt; Ximena Camacho; Claire Vajdic; Louisa Degenhardt; Tracey-Lea Laba; Jodie Hillen; Christopher Etherton-Beer; David Preen; Louisa Jorm; Natasha Donnolley; Alys Havard; Sallie-Anne Pearson
Journal:  Int J Popul Data Sci       Date:  2022-06-13

7.  Metabolic events associated with the use of antipsychotics in children, adolescents and young adults: a multinational sequence symmetry study.

Authors:  Kenneth K C Man; Shih-Chieh Shao; Nathorn Chaiyakunapruk; Piyameth Dilokthornsakul; Kiyoshi Kubota; Junqing Li; Nobuhiro Ooba; Nicole Pratt; Anton Pottegård; Lotte Rasmussen; Elizabeth E Roughead; Ju-Young Shin; Chien-Chou Su; Ian C K Wong; Yea-Huei Kao Yang; Edward Chia-Cheng Lai
Journal:  Eur Child Adolesc Psychiatry       Date:  2020-11-13       Impact factor: 4.785

8.  Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six Countries.

Authors:  Elizabeth E Roughead; Esther W Chan; Nam-Kyong Choi; Michio Kimura; Tomomi Kimura; Kiyoshi Kubota; Edward Chia-Cheng Lai; Kenneth K C Man; Tuan Anh Nguyen; Nobuhiro Ooba; Byung-Joo Park; Tsugumichi Sato; Ju-Young Shin; TongTong Wang; Jenna Griffiths; Ian C K Wong; Yea-Huei Kao Yang; Nicole L Pratt
Journal:  Drug Saf       Date:  2015-09       Impact factor: 5.606

Review 9.  Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.

Authors:  Hai Bo Haber Xue; Li Liu; Hena Zhang; William Montgomery; Tamás Treuer
Journal:  Neuropsychiatr Dis Treat       Date:  2014-05-16       Impact factor: 2.570

10.  Real-world evidence of population differences in allopurinol-related severe cutaneous adverse reactions in East Asians: A population-based cohort study.

Authors:  Tsugumichi Sato; Ching-Lan Cheng; Heung-Woo Park; Yea-Huei Kao Yang; Min-Suk Yang; Mizuki Fujita; Yuji Kumagai; Masahiro Tohkin; Yoshiro Saito; Kimie Sai
Journal:  Clin Transl Sci       Date:  2021-01-27       Impact factor: 4.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.